4,580 Shares in ResMed Inc. $RMD Purchased by Genus Capital Management Inc.

Genus Capital Management Inc. acquired a new position in ResMed Inc. (NYSE:RMD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,580 shares of the medical equipment provider’s stock, valued at approximately $1,182,000.

Several other institutional investors have also bought and sold shares of the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in ResMed by 15.3% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 235,061 shares of the medical equipment provider’s stock worth $60,646,000 after purchasing an additional 31,190 shares during the period. Crestwood Advisors Group LLC acquired a new stake in ResMed in the 2nd quarter valued at about $264,000. Fullcircle Wealth LLC lifted its holdings in ResMed by 7.1% in the 2nd quarter. Fullcircle Wealth LLC now owns 1,037 shares of the medical equipment provider’s stock valued at $268,000 after acquiring an additional 69 shares during the last quarter. W.G. Shaheen & Associates DBA Whitney & Co lifted its holdings in ResMed by 2.0% in the 2nd quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 53,531 shares of the medical equipment provider’s stock valued at $13,811,000 after acquiring an additional 1,043 shares during the last quarter. Finally, Telos Capital Management Inc. lifted its holdings in ResMed by 0.7% in the 2nd quarter. Telos Capital Management Inc. now owns 30,721 shares of the medical equipment provider’s stock valued at $7,926,000 after acquiring an additional 216 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Stock Down 0.5%

Shares of ResMed stock opened at $245.20 on Thursday. The stock has a market capitalization of $35.78 billion, a P/E ratio of 25.78, a PEG ratio of 1.75 and a beta of 0.87. The company has a quick ratio of 2.53, a current ratio of 3.44 and a debt-to-equity ratio of 0.11. The stock has a 50 day moving average price of $269.52 and a two-hundred day moving average price of $261.80. ResMed Inc. has a 12-month low of $199.92 and a 12-month high of $293.81.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 30th. The medical equipment provider reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. ResMed had a return on equity of 25.62% and a net margin of 27.22%.The company had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the prior year, the business earned $2.20 earnings per share. ResMed’s revenue for the quarter was up 9.1% compared to the same quarter last year. Equities analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Thursday, November 13th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, November 13th. ResMed’s dividend payout ratio (DPR) is 24.56%.

Insider Buying and Selling

In related news, General Counsel Michael J. Rider sold 100 shares of the firm’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $274.36, for a total value of $27,436.00. Following the completion of the transaction, the general counsel directly owned 11,327 shares of the company’s stock, valued at $3,107,675.72. This trade represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the firm’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $282.85, for a total value of $2,265,345.65. Following the completion of the transaction, the chief executive officer directly owned 467,792 shares of the company’s stock, valued at approximately $132,314,967.20. This trade represents a 1.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 10,684 shares of company stock valued at $3,032,064 over the last ninety days. 0.65% of the stock is owned by company insiders.

Analyst Ratings Changes

RMD has been the subject of a number of analyst reports. William Blair raised shares of ResMed to a “strong-buy” rating in a research note on Friday, August 1st. Royal Bank Of Canada upped their target price on ResMed from $300.00 to $303.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Citigroup assumed coverage on ResMed in a report on Thursday, September 18th. They issued a “buy” rating and a $330.00 target price on the stock. UBS Group upgraded ResMed to a “strong-buy” rating in a report on Tuesday, September 16th. Finally, Wall Street Zen downgraded ResMed from a “buy” rating to a “hold” rating in a report on Sunday, August 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $297.45.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.